Related Experiment Video
Updated: Jun 3, 2025
00:04
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
10.6K
Interim Clinical Trial Data: Who Can See What, and When?
1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. sellenbe@pennmedicine.upenn.edu.
Therapeutic Innovation & Regulatory Science
|January 8, 2025
Summary
This study addresses challenges in randomized clinical trials by proposing methods to limit access to interim data. These approaches aim to maintain trial integrity while allowing necessary reviews for serious outcomes.
Area of Science:
- Clinical Trials Methodology
- Biostatistics
- Regulatory Science
Background:
- Traditionally, interim data in clinical trials for serious outcomes is kept confidential from investigators and sponsors.
- Independent Data Monitoring Committees (DMCs) are responsible for regular interim data reviews.
- Confidentiality challenges arise when sponsors or regulators need interim data access for trials, such as for accelerated approval pathways.
Purpose of the Study:
- To propose novel approaches for minimizing interim data exposure in ongoing clinical trials.
- To balance the need for data review with the principle of data inaccessibility.
Main Methods:
- The paper outlines strategies for selective data sharing.
- Focuses on methods to reduce the scope of accessible interim data.
Main Results:
- Proposed approaches aim to reduce the risk of bias introduction.
- Facilitates regulatory and sponsor reviews without compromising trial integrity.
Conclusions:
- Implementing these methods can help preserve the integrity of randomized clinical trials.
- Offers solutions for managing interim data access in critical public health research.
Related Concept Videos
01:11Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
01:16Clinical Trials
6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.6K
01:28Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
119
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
119
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
41
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
41
01:12Hazard Ratio
85
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
85